Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – 11 to 14 amino acid residues in defined sequence
Reexamination Certificate
2006-05-25
2008-07-01
TSang, Cecilia (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
11 to 14 amino acid residues in defined sequence
C514S002600
Reexamination Certificate
active
07393919
ABSTRACT:
Human proIslet Peptides (HIP) and HIP analogs and derivatives thereof, derived from or homologous in sequence to the human REG3A protein, chromosome 2p12, are able to induce islet neogenesis from endogenous pancreatic progenitor cells. Human proIslet Peptides are used either alone or in combination with other pharmaceuticals in the treatment of type 1 and type 2 diabetes and other pathologies related to aberrant glucose, carbohydrate, and/or lipid metabolism, insulin resistance, overweight, obesity, polycystic ovarian syndrome, eating disorders and the metabolic syndrome.
REFERENCES:
patent: 4444887 (1984-04-01), Hoffmann
patent: 4716111 (1987-12-01), Osband et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225539 (1993-07-01), Winter
patent: 5403484 (1995-04-01), Ladner et al.
patent: 5427908 (1995-06-01), Dower et al.
patent: 5516637 (1996-05-01), Huang et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5571698 (1996-11-01), Ladner et al.
patent: 5580717 (1996-12-01), Dower et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5658727 (1997-08-01), Barbas et al.
patent: 5698426 (1997-12-01), Huse
patent: 5733743 (1998-03-01), Johnson et al.
patent: 5750753 (1998-05-01), Kimae et al.
patent: 5766886 (1998-06-01), Studnicka et al.
patent: 5780225 (1998-07-01), Wigler et al.
patent: 5807715 (1998-09-01), Morrison et al.
patent: 5821047 (1998-10-01), Garrard et al.
patent: 5834590 (1998-11-01), Vinik et al.
patent: 5840531 (1998-11-01), Vinik et al.
patent: 5969108 (1999-10-01), McCafferty
patent: 6311415 (2001-11-01), Lind
patent: 6407213 (2002-06-01), Carter et al.
patent: RE39062 (2006-04-01), Vinik et al.
patent: RE39299 (2006-09-01), Vinik et al.
patent: 2003/0212000 (2003-11-01), Van Antwerp
patent: 2004/0132644 (2004-07-01), Vinik et al.
patent: 2005/0084449 (2005-04-01), Landes et al.
patent: 239400 (1994-08-01), None
patent: 0592106 (2004-11-01), None
patent: 0519596 (2005-02-01), None
patent: WO 90/02809 (1990-03-01), None
patent: WO 91/09967 (1991-07-01), None
patent: WO 91/10737 (1991-07-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/16428 (1991-10-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/22324 (1992-12-01), None
patent: WO 93/11236 (1993-06-01), None
patent: WO 9317105 (1993-09-01), None
patent: WO 95/15982 (1995-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 96/26215 (1996-06-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13844 (1997-04-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/46645 (1998-10-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 2006/096565 (2006-09-01), None
Rigg et al., Effects of Exogenous insulin on excursions and diurnal rhythm of plasma glucose in pregnant diabetic patients with and without residual, 1980, Am. J. Obstet. Gynecol. 136:537-544.
Buse et al., Amylin replacement with pramlintide in type 1 and type 2 diabetes: A physiological approach to overcome barriers with insulin therapy, 2002, Clin. Diab. 20:137-144.
Rafaeloff et al., Cloning and Sequencing of the Pancreatic Islet Neogenesis Associated Protein (INGAP) Gene and Its Expression in Islet Neogenesis in Hamsters, J. Clin. Invest., May 1997, 99(9):2100-2109.
Lewis et al., Improved glucose control in nonhospitalized pregnant diabetic patients, 1976, Obstet. Gynecol. 48(3):260-267.
Ilic et al., Is the paradoxical first trimester drop in insulin requirement due to an increase in C-peptide concentration in pregnant Type I diabetic women? 2000, Diabetologia 43:1329-1330.
Jovanovic et al., Declining Insulin Requirement in the Late First Trimester of Diabetic Pregnancy, 2001, Diabetes Care 24:1130-1136.
Holick et al., Prevalence of Vitamin D Inadequecy among Postmenopausal North American Women Receiving Osteoporosis Therapy, 2005, J. Clin. Endocrinol. Metab. 90(6):3215-3224.
Riachy et al., 1,25-dihydroxyvitamin D3protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the fas receptor, Feb. 2006, Apoptosis 11(2):151-159.
Holick, High Prevalence of Vitamin D Inadequacy and Implications for Health, Mar. 2006, Mayo Clin. Proc. 81(3):353-373.
Grant, Epidemiology of disease risks in relation to vitamin D insufficiency, Feb. 28, 2006, Prog. Biophys. Mol. Biol. 92:65-79.
Dicesar et al., Vitamin D Deficiency is More Common in Type 2 Than in Type 1 Diabetes, Jan. 2006, Diabetes Care, 29(1):174.
Reis et al., Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease: A review of evidence, 2005, Diabetes Metab. 31(4 pt 1):318-325.
Pozzilli et al., Low Levels of 25-hydroxyvitamin D3and 1.25-dihydroxyvitamin D3in Patients with Newly Diagnosed Type 1 Diabetes, 2005, Horm. Metab. Res. 37(11):680-683.
Heaney et al., Human serum 25-hydroxycholecaliciferol response to extended oral dosing with cholecalciferol1-3, 2003, Am J. Clin. Nutr. 77:204-210.
Vieth et al., Efficacy and safety of vitamin D3intake exceeding the lowest observed adverse effect level1-3, 2001, Am. J. Clin. Nutr. 73:288-294.
Ausubel et al. eds., Current Protocols in Molecular Biology, John Wiley & Sons, 2006 (TOC).
Yoon et al., Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea, 2003, J. Clin. Endocrinol. Metab. 88:2300-2308.
Li et al., Islet loss and alpha cell expansion in type 1 diabetes induced by multiple low-dose steptozotocin administration in mice, 2000, J. Endocrinol. 165:93-99.
Vukkadapu et al., Dynamic interaction between T cell-mediated β-cell damage and β-cell repair in the run up to autoimmune diabetes of the NOD mouse, Apr. 14, 2005, Physiol. Genomics, 21(2):201-211.
Hao et al., Beta-cell differentiation from nonendocrine epithelial cells of the adult human pancreas, 2006, Nature Medicine 12(3):310-316.
Jamal et al., Morphogentic plasticity of adult human pancreatic islets of Langerhans, Jul. 2005, Cell Death Differ. 12(7):702-712.
Ausubel et al. eds., Short Protocols in Molecular Biology, 2nded., A Compedium of Methods from Current Protocols in Molecular Biology, John Wiley & Sons, 1992 (TOC).
Levetan et al., Reduced Glucose Fluctuations Following 4 Weeks of Pramlintide Treatment in Patients with Type 1 Diabetes Intensively Treated with Insulin Pumps, 2002, Diabetes 51(suppl. 2):429-P.
Want et al., Reduced Postprandial Glucose, Glucagon and Triglyceride Excursions Following 4 Weeks of Pramlintide Treatment in Patients with Type 1 Diabetes Treated Intensively with Insulin Pumps. 2002. Diabetes 51(suppl. 2):474.
Levetan, Impact of Pramlintide on the Amplitude of Glycemic Excursions, 2001, Diabetes 50(suppl. 2):2105-PO.
Levetan et al., Impact of Pramlintide on Glucose Fluctuations and Postprandial Glucose, Glucagon, and Triglyceride Excursions Among Patients with Type 1 Diabetes Intensively Treated with Insulin Pumps. 2003, Diabetes Care 26(1):1-8.
Herold et al., A Single Course of Anti-CD3 Monoclonal Antibody hOKT3y1 (Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes. 2005, Diabetes 54(6):1763-1769.
Raz et al., β-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomized, double-blind, phase II trial, 2002, Lancet, 358:1749-1753.
Agardh et al., Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes, 2005, J. Diabetes Complications, 19(4):238-246.
Rosenberg et al., Trophic Stimulation of the Ductular-Islet Cell Axis: A New Approach to the Treatment of Diabetes, 1992, Adv. Exp. Med. Biol. 321:95-104.
Rosenberg et al., Islet-cell regeneration in the diabetic hamster pancreas with restoration of normoglycaemia can be induced by a local growth factor(s), Mar. 1996, Diabetologia 39(3):256-262.
Rosenberg et al., Induction of Islet C
Levetan Claresa S.
Upham Loraine V.
Audet Maudy
Cure DM, Inc.
Pepper Hamilton LLP
TSang Cecilia
LandOfFree
Peptides, derivatives and analogs thereof, and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides, derivatives and analogs thereof, and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides, derivatives and analogs thereof, and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3972017